Valuation: Valneva SE

Market Cap 49Cr 54Cr 45Cr 41Cr 76Cr 5.15TCr 77Cr 536.67Cr 213.76Cr 2.7TCr 203.06Cr 198.78Cr 8.56TCr P/E 2026 *
-5.88x
P/E 2027 * 9.27x
Enterprise Value 62Cr 69Cr 57Cr 52Cr 97Cr 6.58TCr 98Cr 684.98Cr 272.83Cr 3.44TCr 259.18Cr 253.71Cr 11TCr EV / Sales 2026 *
4.11x
EV / Sales 2027 * 1.94x
Free-Float
89.58%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week+6.38%
Current month-5.83%
1 month-5.02%
3 months+15.74%
6 months+9.62%
Current year-31.36%
1 week 2.33
Extreme 2.326
2.57
1 month 2.33
Extreme 2.326
2.77
Current year 2.03
Extreme 2.033
5.15
1 year 2.03
Extreme 2.033
5.15
3 years 1.73
Extreme 1.726
7.17
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
27/01/26 Sell

Chief Technology Officer

11,800 0.0069%
26/01/26 Sell

Chief Financial Officer

11,800 0.0069%
19/01/26 Exercice

Chief Technology Officer

82,899 0.0482%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%+6.38%-35.52%-51.05% 54Cr
+0.65%-3.36%+36.98%+60.50% 6.41TCr
+1.05%+2.78%+12.36%+84.09% 5.55TCr
+1.27%+1.62%+12.87%+104.94% 5.3TCr
+2.76%+0.87%+27.92%+55.07% 4.6TCr
+2.00%-3.39%+17.83%+119.04% 4.25TCr
+1.34%-2.86%+224.43%+914.08% 4.04TCr
+0.64%-3.95%+11.15%+45.57% 3.23TCr
-1.72%+42.46%+103.39%+89.90% 3.45TCr
-2.72%-0.44%+23.18%-10.77% 2.42TCr
Average +0.51%+4.03%+43.46%+141.14% 3.93TCr
Weighted average by Cap. +0.85%+3.49%+49.17%+160.16%

Financials

2026 *2027 *
Net sales 15Cr 17Cr 14Cr 13Cr 24Cr 1.6TCr 24Cr 166.72Cr 66Cr 837.77Cr 63Cr 62Cr 2.66TCr 28Cr 32Cr 26Cr 24Cr 44Cr 3.01TCr 45Cr 313.16Cr 124.73Cr 1.57TCr 118.49Cr 115.99Cr 5TCr
Net income -8.14Cr -9.07Cr -7.52Cr -6.81Cr -13Cr -863.59Cr -13Cr -90Cr -36Cr -451.9Cr -34Cr -33Cr -1.43TCr 5.3Cr 5.91Cr 4.9Cr 4.44Cr 8.29Cr 562.86Cr 8.39Cr 59Cr 23Cr 294.53Cr 22Cr 22Cr 935.03Cr
Net Debt 13Cr 15Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 148.31Cr 59Cr 745.26Cr 56Cr 55Cr 2.37TCr 6.29Cr 7.01Cr 5.81Cr 5.26Cr 9.83Cr 667.26Cr 9.95Cr 69Cr 28Cr 349.16Cr 26Cr 26Cr 1.11TCr
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
29/26/29 €2.569 +0.35% 96,330
28/26/28 €2.560 +3.35% 4,01,463
27/26/27 €2.477 +2.40% 3,08,611
26/26/26 €2.419 +4.00% 4,97,506
23/26/23 €2.326 -3.04% 3,55,632
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Valneva SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.560EUR
Average target price
6.200EUR
Spread / Average Target
+142.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Valneva SE